Pfizer, Inc. (NYSE: PFE) announced the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN (somatropin) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE